States Diverge Sharply on Kratom Regulation as Opioid-Like Supplement Gains Popularity

Rhode Island made history April 1 when legislation overturning the state's kratom ban took effect, making it the first jurisdiction in the United States to reverse prohibition of the psychoactive plant sold widely in convenience stores, smoke shops, and online marketplaces. The reversal arrives amid intensifying legislative activity across the country, where states are pursuing sharply divergent approaches to regulating a substance advocates describe as a harm-reduction tool for opioid withdrawal and critics call "gas station heroin."

Within days of Rhode Island's ban reversal, Connecticut finalized legislation adding kratom to the state schedule of controlled substances, effectively criminalizing its manufacture, sale, and possession. Kansas lawmakers sent a similar Schedule I classification bill to the governor's desk. Meanwhile, Delaware's legislature is considering two competing proposals: one would ban kratom outright, the other would create a regulatory framework acknowledging the substance's use by people managing opioid dependence, chronic pain, and mental health conditions.

The flurry of state action reflects the absence of federal intervention on kratom, a botanical product derived from the leaves of Mitragyna speciosa, a tree in the coffee family native to Southeast Asia. The Food and Drug Administration has signaled intentions to schedule 7-hydroxymitragynine—a compound found in kratom that binds to opioid receptors in the brain—as a controlled substance, but no formal rulemaking has advanced. Without federal guardrails, state legislatures have become the primary policymakers, and their decisions are creating a fragmented regulatory landscape where the same product sold legally in one state carries criminal penalties across the border.

Three Paths, Fifty Laboratories

Analysis from the Rockefeller Institute of Government identifies three dominant policy preferences emerging from state legislatures: outright bans, scheduling kratom or its active compounds as controlled substances, or creating regulated commercial markets through consumer protection acts modeled on industry-supported templates.

Wisconsin, Indiana, Alabama, and Vermont previously enacted kratom bans. This legislative session saw additional prohibition bills introduced in Delaware, Illinois, Michigan, South Dakota, and Tennessee. Ohio implemented an emergency rule banning synthetic kratom products, set to expire in June unless the legislature codifies it permanently. Several localities have moved faster than their state governments: Albuquerque, Kansas City, Nassau County, and Spokane all enacted kratom bans through municipal ordinances.

Scheduling legislation—typically classifying kratom or 7-hydroxymitragynine as Schedule I controlled substances—has been introduced in Idaho, Iowa, Georgia, Nebraska, New York, North Carolina, Pennsylvania, and Texas. Schedule I designation indicates high potential for abuse, no accepted medical use, and lack of safety even under medical supervision. The classification places kratom alongside heroin, LSD, and MDMA in state legal frameworks, making possession a criminal offense.

The third pathway involves regulatory frameworks short of prohibition. These kratom consumer protection acts generally impose age restrictions (usually 21 and older), require independent laboratory testing before products reach market, limit concentrations of 7-hydroxymitragynine to around 2 percent, prohibit packaging attractive to children, ban vaporizable or combustible formulations, and mandate labeling disclosing ingredients, alkaloid content, suggested serving sizes, and warnings that products are not FDA-approved. Variations of consumer protection legislation have been introduced in Hawaii, Idaho, Illinois, Massachusetts, Maryland, Michigan, Ohio, Pennsylvania, Washington, and Wyoming. Nebraska passed such legislation this session.

Rhode Island's reversal of its ban followed this regulatory model. The legislation, enacted in 2025 and effective April 1, 2026, requires retailers to obtain licenses and complete training similar to protocols for tobacco products. The law bans synthetic 7-hydroxymitragynine formulations while permitting natural kratom leaf products to adults 21 and older, with sales subject to an excise tax. The Rhode Island Department of Health is responsible for licensing and oversight, though the timeline for issuing the first licenses and products appearing on shelves remains unclear.

Notably, Florida may soon see its kratom restrictions lapse. The state's attorney general issued an emergency order in August 2025 scheduling 7-hydroxymitragynine concentrated above 1 percent, but the administrative action expires June 30, 2026. The Florida legislature considered several bills this session that would have maintained the ban through statutory law, but the session ended in March without passage, potentially allowing kratom products to return to Florida retail shelves by summer.

The Harm Reduction Debate

Legislative hearings across the country have featured testimony from individuals describing kratom as a lifeline during opioid withdrawal and recovery. Misty Brown, testifying before Delaware lawmakers in March, said kratom quieted her cravings for pain medication and street drugs, creating space to heal. Brown described not returning to pain management clinics for more than six years, now functioning as a mother and grandmother rather than someone cycling through addiction treatment.

Such accounts align with survey data suggesting kratom use is concentrated among people seeking alternatives to prescription opioids or managing withdrawal from more dangerous substances. A 2021 SAMHSA national survey found approximately 1.7 million Americans ages 12 and older had used kratom in the prior year, though industry-supported research published in Frontiers in Pharmacology estimates between 10 million and 16 million people consume kratom products. The discrepancy likely reflects underreporting in federal surveys and the product's rapid growth in recent years.

Kratom leaves contain two primary alkaloids: mitragynine and 7-hydroxymitragynine. At lower doses, users report stimulant-like effects including increased energy and alertness. Higher doses produce opioid-like effects: pain relief, sedation, and relaxation. The compounds bind to mu-opioid receptors in the brain—the same receptors activated by morphine, fentanyl, and prescription painkillers—though kratom's pharmacology differs from classical opioids in ways not yet fully understood.

Delaware state Representative Melanie Ross Levin, a pharmacist sponsoring regulatory legislation, emphasized the need to acknowledge harm-reduction applications while implementing safeguards. Her bill would ban kratom products containing contaminants, exceeding specified 7-hydroxymitragynine thresholds, or containing synthetically derived compounds. It would prohibit sales to those under 21 and restrict packaging designed to attract minors. Ross Levin described the approach as creating regulatory structure for a substance currently facing little oversight in Delaware while recognizing legitimate uses for people managing opioid dependence, chronic pain, or mental health conditions.

Opponents argue no level of regulation makes kratom safe. Delaware state Senator Kyra Hoffner, sponsoring prohibition legislation, said kratom products sold beside energy drinks in gas stations with no physician involvement and no safeguards beyond retailer discretion represent unacceptable public health risks. Hoffner's bill would criminalize manufacture, sale, and distribution of kratom in both natural and synthetic forms, though she indicated plans to amend the legislation removing criminal penalties for simple possession.

Safety Concerns and Federal Silence

The FDA has documented reports of harmful effects associated with 7-hydroxymitragynine products, including addiction, anxiety, depression, gastrointestinal distress, insomnia, seizures, and withdrawal symptoms. The National Institute on Drug Abuse acknowledges kratom products have been linked to a small number of deaths, though nearly all cases involved other drugs or contaminants rather than kratom alone.

Calls to poison control centers involving kratom have surged dramatically. Data compiled by researchers and cited by public health officials show a 1,200 percent increase in kratom-related poison center contacts over the past decade. The majority of calls involve synthetic or concentrated 7-hydroxymitragynine formulations rather than traditional kratom leaf products, which contain lower alkaloid concentrations and are consumed differently than vaporizable liquids or high-dose capsules marketed under brand names suggesting recreational use.

Advocates for regulatory approaches rather than outright bans point to this distinction, arguing that conflating traditional kratom leaf products with synthetic concentrates obscures meaningful differences in risk profiles. The American Kratom Association, which has lobbied for consumer protection legislation in multiple states, emphasizes that properly regulated kratom products can provide safer alternatives to unregulated markets or more dangerous substances. Critics counter that the association represents commercial interests seeking to preserve market access rather than prioritizing public health.

The federal government's hesitance to act definitively on kratom creates the conditions for state-by-state policymaking. The Drug Enforcement Administration floated the possibility of scheduling kratom as a controlled substance in 2016 but withdrew the proposal after public comment and Congressional pressure. The FDA has issued warnings, seized shipments, and pursued enforcement actions against specific kratom products making unsubstantiated health claims, but has not approved kratom as a dietary supplement or moved to schedule it under the Controlled Substances Act.

In February 2026, the FDA announced plans to restrict products containing 7-hydroxymitragynine, focusing regulatory attention on synthetic concentrates rather than natural kratom leaf. The agency's statement emphasized that the action would not target traditional kratom products, though implementation details and timelines remain unspecified. The announcement came as multiple states were already advancing their own legislative responses, suggesting federal action may arrive too late to prevent the balkanized regulatory landscape now emerging.

Implementation Questions

Rhode Island's experience implementing kratom legalization will likely inform debates in other states. The law requires licensing, training, and taxation infrastructure that the Department of Health must develop before products can legally reach consumers. Representative Michelle McGaw, a pharmacist representing Portsmouth, expressed concerns about legalizing a substance acting directly on opioid receptors without the clinical trials and drug approval processes applied to pharmaceutical medications. McGaw is advocating for additional safety measures including requirements that kratom be stored behind locked cabinets, similar to restrictions on certain over-the-counter medications with abuse potential.

The tension between pharmaceutical regulatory standards and botanical product markets runs through kratom policy debates. Prescription medications undergo years of clinical trials documenting safety, efficacy, appropriate dosing, contraindications, and side effect profiles before FDA approval. Dietary supplements, while regulated for purity and labeling accuracy, do not require pre-market approval demonstrating therapeutic benefit. Kratom occupies ambiguous space: marketed as a dietary supplement but consumed by many specifically for opioid-like effects, used by some as self-medication for conditions that would otherwise require prescription treatments, and sold alongside energy drinks and nutritional products despite containing psychoactive alkaloids.

Delaware's competing bills illustrate the policy stakes. Hoffner's prohibition approach treats kratom as inherently too dangerous for any legal market. Ross Levin's regulatory framework accepts that kratom markets already exist, that some Delaware residents use the substance for harm reduction or symptom management, and that the state's role should involve ensuring product safety and limiting youth access rather than criminal prohibition. Both legislators express concerns about kratom's risks; their disagreement centers on whether those risks are best addressed through bans or through regulated markets with consumer protections.

As of April 2026, both Delaware bills remained stalled in committee. Hoffner's prohibition legislation received hearings but has not advanced to floor consideration. Ross Levin's regulatory bill has not yet received a hearing. The Delaware legislature is currently in recess, returning to session April 14. Whether either bill advances, whether a compromise emerges, or whether Delaware joins the growing number of states leaving kratom in legal limbo remains uncertain.

The Opioid Connection

Kratom's role in the broader opioid crisis complicates regulatory decisions. For policymakers focused on reducing overdose deaths and expanding access to evidence-based treatment, kratom presents a dilemma. On one hand, any substance binding to opioid receptors carries inherent risks in a population already struggling with opioid dependence. Substituting one opioid-like substance for another, absent medical supervision and structured treatment plans, contradicts harm reduction principles emphasizing pathways to clinical care rather than self-medication with unregulated products.

On the other hand, testimonies from individuals like Misty Brown suggest kratom may serve as a bridge for people who cannot or will not access conventional addiction treatment. Barriers to medication-assisted treatment remain substantial in many parts of the country: limited provider availability, insurance coverage gaps, transportation challenges, stigma associated with methadone clinics and buprenorphine prescriptions, and waiting lists at treatment facilities. For someone experiencing acute withdrawal, unable to secure a treatment appointment for weeks, kratom purchased at a local convenience store may represent the difference between managing symptoms and returning to street fentanyl.

This reality does not make kratom a substitute for evidence-based treatment. Buprenorphine, methadone, and naltrexone have decades of clinical research demonstrating effectiveness in reducing overdose mortality, criminal activity, infectious disease transmission, and healthcare costs among people with opioid use disorder. Kratom has no such evidence base. But the gap between treatment need and treatment availability means people are making decisions based on what's accessible now, not what clinical guidelines recommend in ideal circumstances.

Legislators voting on kratom bans or regulatory frameworks are effectively deciding whether to eliminate one option people currently use for opioid withdrawal management or to create systems attempting to reduce the risks associated with that use. Neither choice addresses the fundamental problem: insufficient capacity in evidence-based addiction treatment systems to serve everyone who needs help.

States pursuing consumer protection acts may reduce some harms associated with kratom markets. Testing requirements can identify contamination with heavy metals, pathogens, or adulterants. Concentration limits on 7-hydroxymitragynine can prevent synthetic formulations far more potent than traditional kratom leaf products. Age restrictions and packaging requirements can limit youth access. Labeling mandates can inform consumers about contents, dosing, and risks.

But regulation also legitimizes markets and potentially increases availability. Rhode Island's decision to license and tax kratom sales signals state approval, which may influence consumers weighing whether to try the substance. The American Kratom Association's support for consumer protection legislation reflects the industry's calculation that regulated markets are preferable to outright bans, but consumer advocates worry that industry-backed model legislation prioritizes market access over public health.

What Comes Next

The divergent state responses to kratom will produce natural experiments in drug policy. States banning kratom can examine whether prohibition reduces use or merely shifts consumption to unregulated online markets and neighboring jurisdictions where the substance remains legal. States implementing consumer protection acts can assess whether regulated markets reduce harms compared to unregulated availability. States maintaining legal ambiguity will continue seeing kratom sold in convenience stores with minimal oversight.

Researchers studying kratom face significant challenges. The substance's legal status varies by jurisdiction, making multi-state studies difficult. Kratom products vary widely in alkaloid content, formulation, and purity, complicating efforts to study specific dose-response relationships or safety profiles. The population using kratom is heterogeneous: some consume it for energy and focus, others for pain management, others specifically for opioid withdrawal. Lumping these use cases together in epidemiological research obscures meaningful distinctions.

Clinical trials examining kratom's efficacy for opioid use disorder, chronic pain, or other conditions would require FDA approval and substantial funding, neither of which appears forthcoming. The federal government's classification of kratom in regulatory limbo—neither approved as a medication nor scheduled as a controlled substance—creates obstacles to rigorous research while leaving the market to operate with minimal oversight.

For the estimated millions of Americans currently using kratom, the state-by-state policy divergence creates practical challenges. Products legal in one state become contraband across state lines. People relocating for employment or family reasons may find their harm-reduction strategy criminalized in their new jurisdiction. Travelers carrying kratom through states with bans risk prosecution.

The broader pattern—federal inaction forcing states to develop their own drug policies, resulting in fragmented regulatory landscapes where legality depends on geography—echoes cannabis policy debates. But kratom lacks the cultural visibility and political constituency that drove marijuana reform. The substance remains obscure to most Americans despite millions using it. Legislative debates proceed with limited public attention, shaped by testimony from industry representatives, public health officials, and the relatively small number of people willing to publicly identify as kratom consumers.

As state legislative sessions continue through spring and summer 2026, additional policy decisions will emerge. Kansas's governor will decide whether to sign the Schedule I classification bill. Delaware lawmakers returning from recess will determine whether to advance prohibition, regulation, or neither. Florida's administrative ban on concentrated 7-hydroxymitragynine will either lapse or be codified into statute. Other states with pending legislation will vote on competing visions for kratom policy.

Rhode Island's implementation of its regulatory framework will provide evidence for legislators elsewhere. If licensing proceeds smoothly, testing requirements prevent contaminated products from reaching consumers, and youth access remains restricted, the model may gain adherents. If implementation falters, if products with dangerously high alkaloid concentrations reach markets, or if usage among minors increases, prohibition advocates will cite Rhode Island as a cautionary example.

For people like Misty Brown, who testified that kratom created space to heal from opioid addiction, the policy debates are not abstract. The difference between regulated access, unregulated access, and criminal prohibition determines whether the substance that helped her maintain recovery remains available, becomes riskier to obtain, or disappears entirely from legal markets.

The tension between individual autonomy, public health, harm reduction, and paternalism runs through every legislative hearing on kratom. How much risk should adults be permitted to accept when using substances that may help some people while harming others? When does state intervention to prevent potential harm create greater harm by eliminating options people rely on? How should policymakers weigh testimonies from individuals describing kratom as essential to their recovery against public health data documenting adverse events and poison center calls?

These questions have no easy answers, which is perhaps why fifty state legislatures are arriving at fifty different conclusions. The result is a regulatory landscape where geography determines legality, where access depends on which side of a state border someone lives, and where federal silence forces states to make consequential decisions about a substance most Americans have never heard of but millions are quietly using.